Preclinical Market Intelligence, High-Purity Reagents, and Assay Solutions for Glaucoma, Ocular Fibrosis, and Solid Tumor TME Targeting.
TarMart Solution Ecosystem & Related Targets
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | OLFML2B Full-Length Recombinant Protein (Human, Mouse, Cyno) High purity (>95%), Endotoxin <1EU/ug. HEK293 Expressed (Native Glycosylation). Sequence Verified. |
View OLFML2B Products |
| Gene Delivery | OLFML2B Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. CMV promoter. |
View OLFML2B Products |
| Benchmark Ab | Anti-OLFML2B Reference Antibody (Neutralizing) Recombinant positive control for binding, blocking and IHC assays. |
View OLFML2B Products |
| Validator | OLFML2B siRNA Set (3 Unique Targets) For specific knockdown and phenotypic verification. |
View OLFML2B Products |
| Related Target A | OLFML2A (Olfactomedin-Like 2A) High-homology paralog for selectivity counter-screening. |
View OLFML2A Products |
| Related Target B | MYOC (Myocilin) Trabecular meshwork pathway partner and glaucoma co-target. |
View MYOC Products |
| Related Target C | OLFML3 (Angio-Associated) Synergistic anti-angiogenic pathway member. |
View OLFML3 Products |
| Related Target D | TGFB1 (TGF-beta 1) Critical synergistic node in EMT and cancer-associated fibroblast (CAF) activation. |
View TGFB1 Products |
| Related Target E | STAT3 Downstream oncogenic signaling pathway partner for resistance bypass screening. |
View STAT3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species evaluation (human/mouse/cyno) | Ortholog proteins available with >95% purity, Sequence Verified. |
| Subfamily off-target risk (OLFML2A/2B redundancy) | OLFML2A & OLFML2B protein pair available for cross-screening; Sequence Verified distinct epitopes. |
| Native oligomerization state (Olfactomedin domain forms trimers) | HEK293 expressed protein preserves native folding, disulfide bonds, and glycosylation; Theoretical MW verified by Mass Spec. |
| ECM binding affinity quantification | High-purity antigen for SPR/BLI kinetic analysis; Collagen/Fibronectin competition assays. |
| Lack of reliable assay controls | Recombinant benchmark antibodies and validated siRNA included for standardized ELISA/IHC/knockdown protocols. |
Live OLFML2B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The exploration of OLFML2B as a therapeutic target remains in preclinical and discovery phases, with two primary research directions: ophthalmology (primary open-angle glaucoma, ocular hypertension, fibrotic retinopathy) and oncology (solid tumor microenvironment, anti-angiogenesis, EMT, and immune evasion). The olfactomedin family, particularly OLFML2B, modulates extracellular matrix (ECM) structural organization and cell adhesion. Unlike established targets such as VEGF or IOP-lowering small molecules, OLFML2B offers a unique mechanism involving ECM dynamics and angiogenic signaling. Current R&D modalities include neutralizing antibodies, gene therapy (shRNA/CRISPR), recombinant decoy receptors, ADCs, and ECM-disrupting peptides. Future strategies are focused on paralog-selective inhibitors (avoiding OLFML2A redundancy), combination therapies with VEGF/TGF-beta blockade to overcome resistance, and sustained intraocular delivery formats for ophthalmology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Neutralizing Antibodies (mAbs) | Academic Consortia, Early Biotech | Primary Open-Angle Glaucoma, Ocular Hypertension, Solid Tumors (Angio-Inhibition) | Species cross-reactivity panel (Human/Cyno/Mouse); OLFML2A selectivity screen; high-affinity ECD binding using oligomeric native protein. |
| Gene Modulation (shRNA/CRISPR/RNAi) | Gene Therapy Platforms, Target Discovery Labs | Refractory Glaucoma, Refractory Solid Tumors | Stable cell line validation using OLFML2B lentivirus; Sequence-verified siRNA sets for knockdown validation. |
| Decoy Receptor (Fc-Fusion) | Preclinical Discovery Biotechs | Ocular Neovascularization, Fibrotic Retinopathy | Oligomerization disruption assay; high-affinity PPI assay using full-length HEK293-expressed antigen. |
| Antibody-Drug Conjugates (ADCs) | Academic/Translational Labs | Stroma-rich Solid Tumors (Gastric, HCC, Breast) | Tumor penetration assays; structurally intact ECM binding domains for ADC targeting. |
| ECM-Disrupting Peptides | Research Institutes | Fibrosis (Pulmonary, Hepatic) | Collagen competition binding; pure antigen for SPR-based kinetic analysis. |
Key Mutations & Functional Domains
OLFML2B contains an Olfactomedin-like domain (UniProt Q68BL8) that mediates ECM interactions and oligomerization. Key single-nucleotide polymorphisms include rs12130792 and rs2499836, which may influence protein stability or disease susceptibility. These variants are essential considerations for developing selective modulators and for patient stratification in future clinical trials.